Seeking Alpha

Amgen exits denosumab partnership

  • Amgen (AMGN -1.3%) ends its collaboration with Glaxo Group (GSK -0.9%) regarding the commercialization of denosumab for osteoporosis indications in certain geographies. The partnership began on July 27, 2009.
  • All commercial activities assigned to GSK other than those in Australia will transition back to AMGN by the end of the year.
  • In exchange for the early termination, AMGN will pay GSK $275M plus $15M in reimbursements for transition-related costs.
Comments (1)
  • Charles A. Smith
    , contributor
    Comments (1079) | Send Message
 AMGN paying GSK because the D-mab market is so lucrative they want it all to themelves? Or are they paying because its a dud, and GSK wants out?
    3 Apr, 01:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: